سعر اميبروستون 24مكجم 30 كبسولة 2025

Lubiprostone 24 mcg oral capsules (Amiprostone, Andalous Pharma, Egypt), a locally acting chloride channel activator laxative; 30 capsules per pack.

• Chronic idiopathic constipation (CIC) in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Opioid-induced constipation (OIC) in adults with chronic non-cancer pain (including chronic pain related to prior cancer or its treatment) who do not need frequent opioid dose escalation.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Irritable bowel syndrome with constipation (IBS-C) in women at least 18 years old.Population: Women >=18 yearsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>4%) in CIC trials: nausea, diarrhoea, headache, abdominal pain, abdominal distension and flatulence.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known or suspected mechanical gastrointestinal obstruction.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Nausea may occur; taking the dose with food may reduce it.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Avoid in severe diarrhoea; stop treatment and contact the prescriber if severe diarrhoea develops.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Syncope and hypotension have been reported after marketing, mostly with 24 mcg twice daily and sometimes within an hour of a dose; risk may increase with diarrhoea, vomiting or blood-pressure-lowering drugs.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Methadone and other diphenylheptane opioidsNonclinical data show dose-dependent reduction of ClC-2 activation by lubiprostone; efficacy may be reduced, and effectiveness in OIC with these opioids has not been established.DailyMed (U.S. National Library of Medicine)

• Limited human data are insufficient to establish a drug-associated risk of adverse developmental outcomes. Plasma lubiprostone is below quantitation, but metabolite M3 is measurable. Animal studies showed no increase in malformations; a dose-dependent increase in fetal loss occurred in guinea pigs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on presence in human milk; lubiprostone and M3 were not found in rat milk. If present, it may cause diarrhoea in the breastfed infant, so monitor the infant; weigh the benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Lubiprostone: Locally acting activator of ClC-2 chloride channels on the apical membrane of the intestinal epithelium; increases chloride-rich intestinal fluid secretion, which increases motility and eases passage of stool.